Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
Amneal Pharmaceuticals's peak revenue was $2.8B in 2024. The peak quarterly revenue was $730.5M in 2024(q4).
Amneal Pharmaceuticals's revenue increased from $1.7b in 2018 to $2.8B currently. That's a 68.01% change in annual revenue.
| Fiscal year / year | Amneal Pharmaceuticals revenue |
|---|---|
| 2018 | $1.7B |
| 2019 | $1.6B |
| 2020 | $2.0B |
| 2021 | $2.1B |
| 2022 | $2.2B |
| 2023 | $2.4B |
| 2024 | $2.8B |
How accurately did Amneal Pharmaceuticals' revenue projections match actual performance?
Amneal Pharmaceuticals saw the greatest revenue growth in 2020, when revenue increased by 22.51%.
Amneal Pharmaceuticals had the lowest revenue growth in 2019, when revenue changed by -2.2%.
| Year | Amneal Pharmaceuticals growth |
|---|---|
| 2019 | -2%↓ |
| 2020 | 23%↑ |
| 2021 | 5%↑ |
| 2022 | 6%↑ |
| 2023 | 8%↑ |
| 2024 | 17%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | $413.8M | $476.5M | $497.5M |
| 2019 | $446.1M | $404.6M | $378.3M | $397.3M |
| 2020 | $498.5M | $464.7M | $519.3M | $510.0M |
| 2021 | $493.1M | $535.1M | $528.6M | $536.9M |
| 2022 | $497.6M | $559.4M | $545.6M | $609.8M |
| 2023 | $557.5M | $599.0M | $620.0M | $617.0M |
| 2024 | $659.2M | $701.8M | $702.5M | $730.5M |
Do you work at Amneal Pharmaceuticals?
Did Amneal Pharmaceuticals meet its revenue projections?
| CEO | Chirag K. Patel |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 6,500 |
| Date Founded | 2002 |
| Headquarters | Bridgewater, New Jersey |
| Number of Locations | 7 |
| Revenue | $2.8B |
| Net Income | -$250,044,000 |
| Gross Proft | $1.0B (2024) |
| Tax Rate | -0.3% |
| Total Assets | $3,799,341,000 |
| Ticker | AMRX |
Amneal Pharmaceuticals received early financing of $854.0M on 2017-10-01.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $854M | 10/2017 |
| Investors | Security type |
|---|---|
| TPG | Post Ipo Equity |
| FMR Co. | Post Ipo Equity |
Amneal Pharmaceuticals's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
Amneal Pharmaceuticals's smallest competitor is Frontage Laboratories with revenue of $560.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Nektar Therapeutics | $83,561 | $98.4M | 718 | - |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 131 |
| Hospira | $64,435 | $4.5B | 19,000 | - |
| Merck | $90,328 | $64.2B | 74,000 | 1,711 |
| Regeneron | $85,589 | $14.2B | 9,123 | 350 |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,722 |
| Amgen | $93,349 | $33.4B | 22,000 | 714 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 744 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Seagen | $85,008 | $2.0B | 900 | - |
Zippia gives an in-depth look into the details of Amneal Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Amneal Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Amneal Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Amneal Pharmaceuticals. The data presented on this page does not represent the view of Amneal Pharmaceuticals and its employees or that of Zippia.
Amneal Pharmaceuticals may also be known as or be related to Amneal Pharmaceuticals, Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals, Inc.